or Try an Advanced Search...

    Technical Analysis for MLYS - Mineralys Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 12.60 -2.02% -0.26
    MLYS closed down 2.02 percent on Wednesday, November 20, 2024, on approximately normal volume. It ran into resistance at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical MLYS trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish 0.00%
    50 DMA Resistance Bearish 0.00%
    Calm After Storm Range Contraction 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    200 DMA Resistance Bearish -2.02%
    Bullish Engulfing Bullish -2.02%
    New Uptrend Bullish -2.02%
    Stochastic Buy Signal Bullish -2.02%
    Lower Bollinger Band Walk Weakness -2.02%
    Older End-of-Day Signals for MLYS ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 18 hours ago
    Down 3% about 18 hours ago
    Rose Above Previous Day's High about 20 hours ago
    50 DMA Resistance about 20 hours ago
    10 DMA Resistance about 20 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    MLYS Chart by TradingView
    Basic chart:

    Profile

    Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Clinical Medicine Hypertension Cardiovascular Disease Treatment Of Hypertension

    Is MLYS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 13 Mineralys Therapeutics Announces Q3 2024 Results and Updates
    Nov 12 Q3 2024 Mineralys Therapeutics Inc Earnings Call
    Nov 12 Mineralys Therapeutics, Inc. (MLYS) Q3 2024 Earnings Call Transcript
    Nov 11 Mineralys Therapeutics GAAP EPS of -$1.13 misses by $0.31
    Nov 11 Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    Nov 11 Earnings Scheduled For November 11, 2024
    Nov 5 Mineralys Therapeutics to Participate in Upcoming Investor Conferences
    Nov 4 Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024
    Oct 30 Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
    Oct 22 Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024
    See more MLYS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 16.905
    52 Week Low 6.06
    Average Volume 177,981
    200-Day Moving Average 12.87
    50-Day Moving Average 13.03
    20-Day Moving Average 13.35
    10-Day Moving Average 12.95
    Average True Range 0.87
    RSI (14) 45.95
    ADX 23.47
    +DI 22.48
    -DI 21.65
    Chandelier Exit (Long, 3 ATRs) 12.65
    Chandelier Exit (Short, 3 ATRs) 13.90
    Upper Bollinger Bands 15.23
    Lower Bollinger Band 11.48
    Percent B (%b) 0.3
    BandWidth 28.02
    MACD Line -0.27
    MACD Signal Line -0.06
    MACD Histogram -0.2129
    Fundamentals Value
    Market Cap 517.92 Million
    Num Shares 41.1 Million
    EPS -1.38
    Price-to-Earnings (P/E) Ratio -9.13
    Price-to-Sales 0.00
    Price-to-Book 2.18
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 13.84
    Resistance 3 (R3) 13.85 13.45 13.63
    Resistance 2 (R2) 13.45 13.14 13.45 13.56
    Resistance 1 (R1) 13.03 12.94 12.83 13.01 13.49
    Pivot Point 12.63 12.63 12.53 12.62 12.63
    Support 1 (S1) 12.20 12.31 12.00 12.19 11.71
    Support 2 (S2) 11.80 12.12 11.80 11.64
    Support 3 (S3) 11.38 11.80 11.57
    Support 4 (S4) 11.36